Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 3, 2010, Pages 929-938

  Bordia, Tanuja ^a   Campos, Carla ^a   McIntosh, J Michael ^b   Quik, Maryka ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; BUPRENORPHINE; COTININE; LEVODOPA; MECAMYLAMINE; NICOTINE; OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DYSKINESIA; LONG TERM CARE; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; SINGLE DRUG DOSE;

AMPHETAMINE; ANIMALS; ANTIPARKINSON AGENTS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BICYCLO COMPOUNDS, HETEROCYCLIC; CALCIUM CHANNEL BLOCKERS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONOTOXINS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; FUNCTIONAL LATERALITY; LEVODOPA; MALE; MECAMYLAMINE; NEOSTRIATUM; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; STEREOTYPED BEHAVIOR;

EID: 77952480048     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.162396     Document Type: Article

References (45)

1. Albuquerque EX, Pereira EF, Alkondon M, and Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73-120.
2. Benabid AL, Chabardes S, Mitrofanis J, and Pollak P (2009) Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 8:67-81.
3. Bordia T, Campos C, Huang L, and Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 327:239-247.
4. Buccafusco JJ, Beach JW, and Terry AV Jr (2009) Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 328:364-370.
5. Buccafusco JJ and Jackson WJ (1991) Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12:233-238.
6. Buccafusco JJ and Terry AV Jr. (2003) The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci 72:2931-2942.
7. Campos C, Perez X, Jordan K, Letchworth S, and Quik M (2009) Nicotinic receptor subtype agonists reduce L-DOPA-induced dyskinetic movements in parkinsonian rats, in Abstracts from Neuroscience 2009; 2009 Oct 17-21; Chicago. Society for Neuroscience, Washington, DC.
8. Carta M, Carlsson T, Muñoz A, Kirik D, and Björklund A (2008) Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res 172:465-478.
9. Cenci MA and Lundblad M (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9:Unit 9.25.
10. Corringer PJ, Sallette J, and Changeux JP (2006) Nicotine enhances intracellular nicotinic receptor maturation: a novel mechanism of neural plasticity? J Physiol Paris 99:162-171.
11. Cucchiaro G, Xiao Y, Gonzalez-Sulser A, and Kellar KJ (2008) Analgesic effects of Sazetidine-A, a new nicotinic cholinergic drug.Anesthesiology 109:512-519.
12. Dekundy A, Lundblad M, Danysz W, and Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76-89. (Pubitemid 46441485)
13. Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, et al. (2008) In vivo activation of midbrain dopamine neurons via sensitized, high-affinity α6 nicotinic acetylcholine receptors. Neuron 60:123-136.
14. Dwoskin LP, Teng L, Buxton ST, and Crooks PA (1999) (S)-(-)-cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J Pharmacol Exp Ther 288:905-911. (Pubitemid 29254125)
15. Exley R, Clements MA, Hartung H, McIntosh JM, and Cragg SJ (2008) α6-Containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 33:2158-2166. (Pubitemid 351992087)
16. Fahn S (2008) How do you treat motor complications in Parkinson's disease: medicine, surgery, or both? Ann Neurol 64:S56-S64.
17. Fox SH, Chuang R, and Brotchie JM (2008) Parkinson's disease: opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res 172:479-494.
18. Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, et al. (2004) TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective, and long-lasting cognitive effects. CNS Drug Rev 10:147-166. (Pubitemid 38879108)
19. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, Moretti M, Pedrazzi P, Pucci L and Zoli M (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 78:703-711.
20. Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, and Marks MJ (2007) The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 74:1235-1246. (Pubitemid 47417935)
21. Grady SR, Salminen O, McIntosh JM, Marks MJ, and Collins AC (2010) Mouse striatal dopamine nerve terminals express α4α5β2 and two stoichiometric forms of α4β*-nicotinic acetylcholine receptors. J Mol Neurosci 40:91-95.
22. Gregório ML, Wietzikoski EC, Ferro MM, Silveira JL, Vital MA, and Da Cunha C (2009) Nicotine induces sensitization of turning behavior in 6-hydroxydopamine-lesioned rats. Neurotox Res 15:359-366.
23. Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, and Quik M (2004) Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2- methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine- induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther 311:770-777. (Pubitemid 39391566)
24. Huang LZ, Bordia T, and Quik M (2009) Nicotine treatment reduces L-DOPA-induced dyskinetic-like movements in parkinsonian mice in Abstracts from Neuroscience 2009; 2009 Oct 17-21; Chicago. Society for Neuroscience, Washington, DC.
25. Hulihan-Giblin BA, Lumpkin MD, and Kellar KJ (1990a) Acute effects of nicotine on prolactin release in the rat: agonist and antagonist effects of a single injection of nicotine. J Pharmacol Exp Ther 252:15-20.
26. Hulihan-Giblin BA, Lumpkin MD, and Kellar KJ (1990b) Effects of chronic administration of nicotine on prolactin release in the rat: inactivation of prolactin response by repeated injections of nicotine. J Pharmacol Exp Ther 252:21-25.
27. Kuryatov A, Luo J, Cooper J, and Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human α4β2 acetylcholine receptors. Mol Pharmacol 68:1839-1851. (Pubitemid 41654365)
28. Lockman PR, McAfee G, Geldenhuys WJ, Van der Schyf CJ, Abbruscato TJ, and Allen DD (2005) Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. J Pharmacol Exp Ther 314:636-642. (Pubitemid 41043844)
29. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, et al. (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 190:269-319.
30. Meyer EL, Yoshikami D, and McIntosh JM (2008) The neuronal nicotinic acetylcholine receptors α4* and α6* differentially modulate dopamine release in mouse striatal slices. J Neurochem 105:1761-1769. (Pubitemid 351678494)
31. O'Leary KT, Parameswaran N, McIntosh JM, and Quik M (2008) Cotinine selectively activates a subpopulation of α3/α6β2* nicotinic receptors in monkey striatum. J Pharmacol Exp Ther 325:646-654. (Pubitemid 351574817)
32. Parameswaran N, Huang LZ, Lee Y, Carroll FI, and Quik M (2009) Effect of nAChR agonists on L-DOPA-induced dyskinesias in parkinsonian rats in Abstracts from Neuroscience 2009; 2009 Oct 17-21; Chicago. Society for Neuroscience, Washington, DC.
33. Perez XA, Bordia T, McIntosh JM, Grady SR, and Quik M (2008) Long-term nicotine treatment differentially regulates striatal.
34. Picciotto MR, Addy NA, Mineur YS, and Brunzell DH (2008) It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84:329-342.
35. Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, Changeux JP, Maskos U, and Fratta W (2008) Crucial role of α4 and α6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci 28:12318-12327.
36. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, and Di Monte D (2007) Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 62:588-596.
37. Quik M, O'Leary K, and Tanner CM (2008) Nicotine and Parkinson's disease: implications for therapy. Mov Disord 23:1641-1652.
38. Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, McIntosh JM, Collins AC, and Grady SR (2003) Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 63:1169-1179. (Pubitemid 36529935)
39. Schallert T, Fleming SM, Leasure JL, Tillerson JL, and Bland ST (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism, and spinal cord injury. Neuropharmacology 39:777-787. (Pubitemid 30103682)
40. Schapira AH, Emre M, Jenner P, and Poewe W (2009) Levodopa in the treatment of Parkinson's disease. Eur J Neurol 16:982-989.
41. Semba J, Mataki C, Yamada S, Nankai M, and Toru M (1998) Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry 43:389-391. (Pubitemid 28139460)
42. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, and Sanberg PR (2002) Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7:525-535.
43. Terry AV, Buccafusco JJ, and Prendergast MA (1999) Dose-specific improvements in memory-related task performance by rats and aged monkeys administered the nicoitnic-cholinerigc antagonist mecamylamine. Drug Dev Res 47:127-136.
44. Tizabi Y, Mastropaolo J, Park CH, Riggs RL, Powell D, Rosse RB, and Deutsch SI (1998) Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: psychiatric implications. Psychopharmacology (Berl) 140:202-205. (Pubitemid 28538480)
45. Vallejo YF, Buisson B, Bertrand D, and Green WN (2005) Chronic nicotine exposure up-regulates nicotinic receptors by a novel mechanism. J Neurosci 25:5563-5572. (Pubitemid 40800648)